TITLE

Bupropion: A Review of its Use in the Management of Smoking Cessation

AUTHOR(S)
Holm, K.J.; Spencer, C.M.
PUB. DATE
April 2000
SOURCE
Drugs;Apr2000, Vol. 59 Issue 4, p1007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an aid to smoking cessation. In 2 large well designed clinical trials, sustained release bupropion 300 mg/day (the recommended dose) for 7 or 9 weeks was associated with considerably and significantly higher smoking abstinence rates (continuous abstinence and 7-day point prevalence rates) than placebo during treatment and at follow-up at 6 and 12 months. Point prevalence rates at 12 months in 2 studies were 23.1 and 30.3% with bupropion, whereas values for placebo were 12.4 and 15.6%. Continuous abstinence rates at 12 months, available from 1 trial, were 18.4% with bupropion and 5.6% with placebo. Furthermore, bupropion was associated with significantly higher quitting rates than nicotine patch in a comparative study. Combination therapy with bupropion and nicotine patch provided slightly higher abstinence rates than bupropion alone, although differences were not statistically significant. The combination was superior to nicotine patch alone. Data from a preliminary report of long term bupropion treatment (52 weeks) showed that the drug was associated with significantly higher continuous abstinence rates than placebo only to 6 months. However, point prevalence abstinence rates were significantly higher with bupropion than placebo to 18 months. Bupropion 300 mg/day recipients reported nicotine withdrawal symptoms during treatment; however, the symptoms were significantly less severe with bupropion than placebo. Patients receiving bupropion 300 mg/day or bupropion in combination with nicotine patch for smoking cessation generally gained less bodyweight than placebo recipients. The benefits of bupropion for preventing weight gain persisted after the completion of long term, but not short term therapy. Bupropion was well tolerated in clinical trials, and the only adverse events that were significantly more common with bupropion than placebo were insomnia and dry mouth. Data published so far suggest that sustained release bupropion has a low potential for inducing seizures (seizure rate ≈0.1% in patients with depression). Conclusions: Bupropion is an effective and well tolerated smoking cessation intervention. Further studies with long term follow-up will be useful in determining whether abstinence rates are maintained with bupropion. In addition, clarification of its efficacy in comparison with other therapies used for smoking cessation would help to establish its clinical value. The reduced potential for weight gain with bupropion and the ability to use bupropion in combination with nicotine replacement therapy make the drug a useful treatment option for smoking cessation.
ACCESSION #
9592793

 

Related Articles

  • Nicotine chewing gum and the medicalization of smoking. Blum, Alan; Blum, A // Annals of Internal Medicine;Jul84, Vol. 101 Issue 1, p121 

    Explores issues related to the nicotine gum as a treatment for smoking prevention. Findings of studies conducted on the efficacy of the gum; Concerns about the introduction of the gum; Conclusion and recommendations.

  • RESOLVE: The world's first all-natural stop-smoking solution.  // Alive: Canada's Natural Health & Wellness Magazine;Oct2006, Issue 288, p122 

    The article evaluates Resolve, a natural stop-smoking lozenge which aid smokers during nicotine withdrawal.

  • Resolve--The world's first all-natural stop smoking solution!  // Alive: Canada's Natural Health & Wellness Magazine;Jan2007, Issue 291, p121 

    The article evaluates the Resolveâ„¢ smoking cessation product.

  • Nicotinell. Boffey, Matt // Marketing (00253650);9/27/2006, p26 

    The article focuses on Nicotinell, the advertisement of which intends to encourage women to use the brand to help them give up smoking. The company has made an advertisement featuring Actor Angelina Jolie look-a-like tearing around on a motorbike in an attempt to create an association in women's...

  • Smoking cessation aid.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p12 

    The article reports that the U.S. Food and Drug Administration has approved Chantix, varenicline tartrate, for helping smokers quit. The efficacy of the treatment was tested in five randomized clinical trials using chronic smokers. Chantix was found to be superior to placebo in helping smokers...

  • Quitting just got cheaper. Ratcliffe, Lucy // New Zealand Doctor;9/9/2009, p9 

    The article focuses on the lowering of prices and easier availability of nicotine replacement therapy (NRT) like patches, gum and lozenges in New Zealand by October 2009. It is stated that the NRT supply for eight weeks will now cost patients, with or without a Quit Card, just 6 New Zealand...

  • Comparing the Tolerability and Effectiveness of Two Treatment Regimens in a Smoking Clinic. Sherman, Scott E.; Aldana, Ileana; Estrada, Maribel; York, Laura // Military Medicine;Jun2008, Vol. 173 Issue 6, p550 

    This study compares the effectiveness and tolerability of bupropion versus bupropion plus nicotine patch for smoking cessation ill a routine clinical setting. Patients at the Sepulveda Veterans Health Administration Smoking Cessation Clinic completed a baseline survey and received counseling...

  • Disparities in Access to Over-the-Counter Nicotine Replacement Products in New York City Pharmacies. Bernstein, Steven L.; Cabral, Lisa; Maantay, Juliana; Peprah, Dorothy; Lounsbury, David; Maroko, Andrew; Murphy, Mary; Shelley, Donna // American Journal of Public Health;Sep2009, Vol. 99 Issue 9, p1699 

    Objectives. We surveyed the availability of tobacco products and nonprescription nicotine replacement therapy (NRT) in pharmacies in New York City, stratified by the race, ethnicity, and socioeconomic status (SES) of the surrounding neighborhoods to determine whether disparities in availability...

  • Resolutions jump-start diet aid, anti-smoking product sales. Johnsen, Michael // Drug Store News;1/14/2008, Vol. 30 Issue 1, p29 

    The article reports on the expected growth in demand of nutritional diet aids and anti-smoking and smoking-alternative products in the U.S. beginning 2008. According to a report from the Nielsen Co., consumers are expected to purchase more than $100 million in such products in pursuant to their...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics